Our top pick for
Evelo Biosciences, Inc is a biotechnology business based in the US. Evelo Biosciences shares (EVLO) are listed on the NASDAQ and all prices are listed in US Dollars. Evelo Biosciences employs 98 staff and has a market cap (total outstanding shares value) of USD$227.5 million.
Since the stock market crash in March caused by coronavirus, Evelo Biosciences's share price has had significant negative movement.
Its last market close was USD$4.72, which is 19.73% down on its pre-crash value of USD$5.88 and 56.81% up on the lowest point reached during the March crash when the shares fell as low as USD$3.01.
If you had bought USD$1,000 worth of Evelo Biosciences shares at the start of February 2020, those shares would have been worth USD$740.12 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$981.29.
|Latest market close||USD$4.72|
|52-week range||USD$3.01 - USD$8.3|
|50-day moving average||USD$4.8943|
|200-day moving average||USD$4.5356|
|Wall St. target price||USD$9.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.27|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-20)||-1.26%|
|1 month (2020-10-29)||8.76%|
|3 months (2020-08-28)||5.83%|
|6 months (2020-05-29)||8.01%|
|1 year (2019-11-29)||4.66%|
|2 years (2018-11-29)||-52.32%|
|3 years (2017-11-26)||N/A|
|5 years (2015-11-26)||N/A|
|Gross profit TTM||USD$0|
|Return on assets TTM||-45.64%|
|Return on equity TTM||-103.87%|
|Market capitalisation||USD$227.5 million|
TTM: trailing 12 months
There are currently 1.7 million Evelo Biosciences shares held short by investors – that's known as Evelo Biosciences's "short interest". This figure is 19.8% up from 1.4 million last month.
There are a few different ways that this level of interest in shorting Evelo Biosciences shares can be evaluated.
Evelo Biosciences's "short interest ratio" (SIR) is the quantity of Evelo Biosciences shares currently shorted divided by the average quantity of Evelo Biosciences shares traded daily (recently around 139740.20950846). Evelo Biosciences's SIR currently stands at 12.41. In other words for every 100,000 Evelo Biosciences shares traded daily on the market, roughly 12410 shares are currently held short.
However Evelo Biosciences's short interest can also be evaluated against the total number of Evelo Biosciences shares, or, against the total number of tradable Evelo Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Evelo Biosciences's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Evelo Biosciences shares in existence, roughly 40 shares are currently held short) or 0.071% of the tradable shares (for every 100,000 tradable Evelo Biosciences shares, roughly 71 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Evelo Biosciences.
Find out more about how you can short Evelo Biosciences stock.
We're not expecting Evelo Biosciences to pay a dividend over the next 12 months.
Over the last 12 months, Evelo Biosciences's shares have ranged in value from as little as $3.01 up to $8.3. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Evelo Biosciences's is 0.8131. This would suggest that Evelo Biosciences's shares are less volatile than average (for this exchange).
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a monoclonal microbial candidate, which is in Phase 1b placebo-controlled dose-escalating safety and tolerability clinical study for the treatment of psoriasis or atopic dermatitis. The company is also developing monoclonal microbial candidates, which are in pre-clinical development stage include EDP1815 for treating psoriatic arthritis, rheumatoid arthritis, and axial spondyloarthritis; EDP1867 for asthma; EDP2939 for inflammatory disease; and EDP1632 for neuro-inflammatory diseases. In addition, it is developing EDP1503, a monoclonal microbial candidate, which is in Phase 1/2 clinical study for the treatment of colorectal cancer, triple-negative breast cancer, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.